Active specific immunotherapy of metastatic melanoma with an antiidiotype vaccine: A phase I/II trial of I-Mel-2 plus SAF-m

Journal of Clinical Oncology

Volumn 15, Issue 5, 1997, Pages 2103-2110

  Quan Jr , Walter D ^a   Dean, Grace E ^a   Spears, Lucy ^a   Spears, C Paul ^a   Groshen, Susan ^a   Merritt, James A ^a   Mitchell, Malcolm S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; IMMUNOLOGICAL ADJUVANT; MELANOMA VACCINE;

ADULT; AGED; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MELANOMA; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; VERTIGO;

EID: 0343376118     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.5.2103     Document Type: Article

References (31)

1. Wingo PA, Tong T, Bolden S: Cancer statistics, 1995. CA 45:8-30, 1995
2. Cohen SM: Chemotherapy of metastatic melanoma. Mt Sinai J Med 59:22-223, 1992
3. Gunderson S: Dacarbazine, vindesine, and cis-platin combination chemotherapy in advanced malignant melanoma: A phase II study. Cancer Treat Rep 71:997-999, 1987
4. Creagan ET, Schaid DJ, Ahmann DL, et al: Disseminated malignant melanoma and recombinant interferon: Analysis of seven consecutive phase II investigations. J Invest Dermatol 95:188s-192s, 1990
5. Bar MH, Sznol M, Atkins MB, et al: Metastatic malignant melanoma treated with combined bolus and continuous infusion interleukin-2 and lymphokine activated killer cells. J Clin Oncol 8:1138-1147, 1990
6. Mitchell MS, Harel W, Kan-Mitchell J, et al: Active specific immunotherapy for melanoma with allogeneic cell lysates: Rationale, results and possible mechanisms of action. Ann NY Acad Sci 690:153-166, 1993
7. Natali PG, Bigotti A, Cavaliere R, et al: Phenotyping of lesions of melanocyte origin with monoclonal antibodies to melanoma-associated antigens and to HLA antigens. J Natl Cancer Inst 73:13-24, 1984
8. Natali PG, Imai K, Wilson BS, et al: Structural properties and tissue distribution of the antigen recognition by the monoclonal antibody 653.40S to human melanoma cells. J Natl Cancer Inst 67:591-601, 1981
9. Natali PG, Bigotti A, Nicotra MR, et al: Analysis of the antigenic profile of uveal melanoma lesions with anti-cutaneous melanoma-associated antigen and anti-HLA monoclonal antibodies. Cancer Res 49:1269-1274, 1989
10. Natali PG, Bigotti A, Cavaliere R, et al: Heterogeneous expression of melanoma-associated antigens and HLA antigens by primary and multiple metastatic lesions removed from patients with melanoma. Cancer Res 45:2883-2889, 1985
11. Schulz G, Staffileno LK, Reisfeld RA, et al: Eradication of established human melanoma tumors in nude mice by antibody-directed effector cells. J Exp Med 161:1315-1325, 1985
12. Chattopadhyay P, Sneed D, Rosenberg J, et al: Monoclonal anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen: Generation and characterization of anti-idiotypic antibodies. Cancer Res 51:3183-3192, 1991
13. Jerne NK: Towards a network theory of the immune response. Ann Immunol (Paris) 125C: 373-389, 1974
14. Johnston D, Bystryn J-C: Effect of the adjuvant SAF-m on the immunogenicity of a murine B16 melanoma vaccine. Vaccine Res 2:55-64, 1993
15. Hariharan K, Braslawsky G, Black A, et al: The induction of cytotoxic T cells and tumor regression by soluble antigen formulation. Cancer Res 55:3486-3489, 1995
16. Livingston PO, Adluri S, Zhang S, et al: Impact of immunological adjuvants and administration route on HAMA response after immunization with murine monoclonal antibody MELIMMUNE-1 in melanoma patients. Vaccine Res 4:87-94, 1995
17. Chattopadhyay P, Kaveri S, Byars N, et al: Human high molecular weight-melanoma associated antigen mimicry by an antiidiotypic antibody: Characterization of the immunogenicity and the immune response to the mouse monoclonal antibody I-Mel-1. Cancer Res 51:6045-6051, 1991
18. Raychaudhuri S, Saeki Y, Fuji H, Kohler H: Tumor-specific idiotype vaccines. I. Generation and characterization of internal image tumor antigen. J Immunol 137:1743-1749, 1986
19. Mitchell MS, Kan-Mitchell J, Kempf RA, et al: Active specific immunotherapy for melanoma: Phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 48:5883-5893, 1988
20. Mitchell MS, Harel W, Kempf RA, et al: Active-specific immunotherapy for melanoma. J Clin Oncol 8:856-869, 1990
21. Morton DL, Foshag LJ, Hoon D, et al: Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216:463-482, 1992
22. Berd D, Mastrangelo MJ: Active immunotherapy of human melanoma exploiting the immunopentiating effects of cyclophosphamide. Cancer Invest 6:337-349, 1988
23. Murray DR, Cassel WA, Torbin AH, et al: Viral oncolysate in the management of malignant melanoma: Clinical studies. Cancer 40:680-686, 1977
24. Anderson DR, Kohler H, Muller S: Biomodulation with network epitopes, in Mitchell MS (ed): Biological Approaches to Cancer Treatment: Biomodulation. New York, NY, McGraw-Hill, 1993, pp 155-171
25. Ferrone S: Active specific immunotherapy with murine antiidiotypic monoclonal antibodies of the high molecular weight-melanoma-associated antigen system, in Balch CM, Houghton AN, Milton GW, et al (eds): Cutaneous Melanoma (ed 2). Philadelphia, PA, Lippincott, 1992, pp 552-559
26. Mittelman A, Chen ZJ, Kageshita T, et al: Active specific immunotherapy in patients with melanoma. A clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight melanoma-associated antigen monoclonal antibodies. J Clin Invest 86:2136-2144, 1990
27. Mittelman A, Chen ZJ, Yang H, et al: Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: Induction of humoral anti-HMW- MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci USA 89:466-470, 1992
28. Sznol M, Clark JW, Smith JW III, et al: Pilot study of interleukin-2 and lymphokine-activated killer cells combined with immunomodulatory doses of chemotherapy and sequenced with interferon alfa-2a in patients with metastatic melanoma and renal cell carcinoma. J Natl Cancer Inst 84:929-937, 1992
29. Margolin KA, Rayner AA, Hawkins MJ, et al: Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: Analysis of toxicity and management guidelines. J Clin Oncol 7:486-498, 1989
30. Mitchell MS: Relapse in the central nervous system in melanoma patients successfully treated with biomodulators. J Clin Oncol 7:121-129, 1989
31. Amer MH, Al-Sarraf M, Vaitkevicius VK: Clinical presentation, natural history, and prognostic factors in advanced malignant melanoma. Surg Gynecol Obstet 149:687-692, 1979